Advisory Research’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Advisory Research’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,455	Closed	-$1.01M	–	513
2023 Q1	$1.01M	Buy	9,455 +3,865	+69%	+$445K	0.17%	152
2022 Q4	$615K	Sell	5,590 -3,117	-36%	-$202K	0.06%	225
2022 Q3	$514K	Buy	+8,707	New	+$398K	0.05%	234

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Advisory Research's RXDX Position: Q2 2023 in Review

Advisory Research sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 9,455 shares — an estimated $1.01M sold.

Advisory Research first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $1.01M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Advisory Research reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Advisory Research sold 9,455 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.01M.
Advisory Research first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Advisory Research's Prometheus Biosciences, Inc. Common Stock position peaked at $1.01M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Advisory Research's 13F filing for Q2 2023, filed 14 Aug 2023.